BioSpace News Archive

Viracta Therapeutics, Inc. (Nasdaq: VIRX), today announced the presentation of new preclinical data on vecabrutinib, a reversible inhibitor of Bruton’s tyrosine kinase (BTK) and interleukin-2-inducible kinase (ITK), in oral and poster presentations at the 2021 American Society of Hematology (ASH) Annual Meeting.

2seventy bio, Inc. (NASDAQ: TSVT) today announced data from its broad oncology cell therapy portfolio, including updated results from the CRB-402 study of bb21217 and new analyses from the pivotal KarMMa study of ABECMA® (idecabtagene vicleucel; ide-cel) for adult patients with relapsed or refractory multiple myeloma, both in partnership with Bristol Myers Squibb (BMS).

Atara Biotherapeutics, Inc. (Nasdaq: ATRA), today announced efficacy and safety results from its Phase 3 multicenter ALLELE study investigating tabelecleucel (tab-cel®) for the treatment of Epstein-Barr virus positive post-transplant lymphoproliferative disease (EBV+ PTLD) following solid organ transplant (SOT) or hematopoietic cell transplant (HCT).

Akumin Inc. announced its financial results for the quarter ended September 30, 2021.

BeiGene and Nanjing Leads Biolabs, Inc. announced entry into a license and collaboration agreement granting BeiGene worldwide research, development and manufacturing rights and exclusive commercialization rights outside of China to LBL-007, a novel investigational antibody targeting the LAG-3 pathway.

InnoCare Pharma, a leading biotech company, announced that leading PIs presented latest data of BTK inhibitor orelabrutinib at the 63rd American Society of Hematology Annual Meeting on December 11-14, 2021, which is hold online and offline in Atlanta, Georgia.

Fate Therapeutics, Inc. (NASDAQ: FATE), today showcased positive interim Phase 1 data from the Company’s FT596 program for patients with relapsed / refractory B-cell lymphoma (BCL) at the 63rd American Society of Hematology (ASH) Annual Meeting and Exposition.

Sigilon Therapeutics, Inc. (NASDAQ: SGTX), a biotechnology company that seeks to develop functional cures for chronic diseases through its Shielded Living Therapeutics™ platform, today announced a strategic reprioritization to enable the Company to focus on MPS-1 and diabetes.

Precigen, Inc., today presented positive interim data at the 63rd ASH Annual Meeting and Exposition (Abstract# 825) from the ongoing Phase 1/1b clinical study of PRGN-3006 UltraCAR-T® in patients with relapsed or refractory (r/r) acute myeloid leukemia (AML) and higher risk myelodysplastic syndromes (MDS) (clinical trial identifier: NCT03927261).

These agreements between Hoth Therapeutics and WuXi STA are expected to accelerate the development of this new modality therapy with rapid and efficient PMO manufacturing scale-up from feasibility batches to GMP material.